MX2012005597A - Formas cristalinas de pirazolopirimidinas sustituidas. - Google Patents

Formas cristalinas de pirazolopirimidinas sustituidas.

Info

Publication number
MX2012005597A
MX2012005597A MX2012005597A MX2012005597A MX2012005597A MX 2012005597 A MX2012005597 A MX 2012005597A MX 2012005597 A MX2012005597 A MX 2012005597A MX 2012005597 A MX2012005597 A MX 2012005597A MX 2012005597 A MX2012005597 A MX 2012005597A
Authority
MX
Mexico
Prior art keywords
acid
crystalline forms
pyrazolopyrimidines
crystal former
disorders
Prior art date
Application number
MX2012005597A
Other languages
English (en)
Inventor
Peter Boderke
Patrick Plitt
Bernhard Hauptmeier
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2012005597A publication Critical patent/MX2012005597A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con cristales mixtos novedosos de pirazolopirimidinas y un formador de cristal mixto, en donde el formador de cristal mixto es un ácido carboxílico orgánico, preferentemente se selecciona del grupo de ácido gentísico, ácido succínico, y ácido xinafóico. Las pirazolopirimidinas, y en particular el compuesto A son potentes moduladores de mGluR5 y son útiles para la prevención y tratamiento de trastornos neurológicos agudos y crónicos, en particular trastornos del CNS (sistema nervioso central), que involucra excesiva excitación inducida por glutamato.
MX2012005597A 2009-11-25 2010-11-24 Formas cristalinas de pirazolopirimidinas sustituidas. MX2012005597A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26426909P 2009-11-25 2009-11-25
EP09177036 2009-11-25
PCT/EP2010/068093 WO2011064237A1 (en) 2009-11-25 2010-11-24 Crystalline forms of substituted pyrazolopyrimidines

Publications (1)

Publication Number Publication Date
MX2012005597A true MX2012005597A (es) 2012-05-29

Family

ID=42145278

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005597A MX2012005597A (es) 2009-11-25 2010-11-24 Formas cristalinas de pirazolopirimidinas sustituidas.

Country Status (13)

Country Link
US (1) US20120283274A1 (es)
EP (1) EP2504340A1 (es)
JP (1) JP2013512216A (es)
KR (1) KR20120098745A (es)
CN (1) CN102695709A (es)
AR (1) AR079143A1 (es)
AU (1) AU2010323209A1 (es)
CA (1) CA2776361A1 (es)
IL (1) IL218717A0 (es)
MX (1) MX2012005597A (es)
RU (1) RU2012126150A (es)
WO (1) WO2011064237A1 (es)
ZA (1) ZA201202097B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
WO2013087815A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2054416T1 (sl) * 2006-08-04 2011-05-31 Merz Pharma Gmbh & Co Kgaa Substituirani pirazolopirimidini, postopek za njihovo pripravo in njihova uporaba kot zdravilo
RU2450004C2 (ru) 2006-08-04 2012-05-10 Мерц Фарма Гмбх Унд Ко. Кгаа Замещенные пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства
EP2085398A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators

Also Published As

Publication number Publication date
WO2011064237A1 (en) 2011-06-03
CA2776361A1 (en) 2011-06-03
US20120283274A1 (en) 2012-11-08
KR20120098745A (ko) 2012-09-05
CN102695709A (zh) 2012-09-26
ZA201202097B (en) 2012-11-28
IL218717A0 (en) 2012-06-28
AU2010323209A1 (en) 2012-06-14
EP2504340A1 (en) 2012-10-03
AR079143A1 (es) 2011-12-28
RU2012126150A (ru) 2013-12-27
JP2013512216A (ja) 2013-04-11

Similar Documents

Publication Publication Date Title
UA106692C2 (uk) ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
WO2012042539A3 (en) 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
IN2014KN00929A (es)
EA201500175A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MX2012005597A (es) Formas cristalinas de pirazolopirimidinas sustituidas.
WO2014152536A3 (en) Inhibitors of leukotriene a4 hydrolase
CU24083B1 (es) Derivados de oxazina útiles como inhibidores de bace para el tratamiento de trastornos neurológicos
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
WO2007081857A3 (en) Cycloalkylamines as monoamine reuptake inhibitors
NO20100078L (no) (2S,3R)-N-(2-((3-pyridinyl)metyl)-1-azabicyklo[2.2.2]oct-3-yl)benzofuran-2-karboksamid, nye saltformer og deres anvendelse
GEP20146169B (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PH12015500085A1 (en) 5-ht3 receptor antagonists
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
WO2012116050A3 (en) Phosphorus containing compounds as protein kinase inhibitors
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
WO2009118765A8 (en) Novel monoamine re-uptake inhibitor
EA201171393A1 (ru) 7-([1,2,4]ТРИАЗОЛО[1,5α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН И ЕГО ПРИМЕНЕНИЕ
MY159040A (en) Compounds
EA201270610A1 (ru) Хинуклидиновые соединения как альфа-7 лиганды ацетилхолинового рецептора
EA201300389A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
MX2015013059A (es) Sales, co-cristales, y polimorfos de un compuesto ansiolitico.
WO2007013936A3 (en) Method for treating nervous system disorders and conditions
DE602007005117D1 (de) Herstellungsverfahren für pyrazolhaltige verbindungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal